Recent clinical studies with small molecule inhibitors, including tyrosine kinase inhibitors, anti-ERBB2 agents, PI3K/Akt/mTOR inhibitors, and CDK4/6 inhibitors, have shown promise in inhibiting proliferation and metastasis in ERBB2+ BC [10,11,12]. Here, MTOR is linked to breast cancer.